Herndon Capital Management’s Eagle Pharmaceuticals, Inc. EGRX Stock Holding History

Herndon Capital Management’s Portfolio EGRX Stock Details EGRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	$3K	Buy	+42	New	+$3.44K	﹤0.01%	191

Other funds holding EGRX

Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Victory Capital Management San Antonio, Texas $156B AUM 27.51% 1-Year Est. Return

HEC

Hudson Executive Capital New York $151M AUM 60.14% 1-Year Est. Return

Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

IAM

Iridian Asset Management Westport, Connecticut $291M AUM 49.45% 1-Year Est. Return

First Eagle Investment Management New York $59B AUM 32.99% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

JAM

JW Asset Management Miami Beach, Florida $244M AUM 71.51% 1-Year Est. Return

Herndon Capital Management's EGRX Position: Q2 2017 in Review

Herndon Capital Management opened a new position in Eagle Pharmaceuticals, Inc. (EGRX) in Q2 2017: 42 shares worth $3K. The stake represents ﹤0.01% of the portfolio and ranks #191 among its holdings.

175 funds tracked by Wall St. Rank hold EGRX as of Q2 2017.

Herndon Capital Management held 42 shares of Eagle Pharmaceuticals, Inc. worth $3K as of Q2 2017.
Eagle Pharmaceuticals, Inc. was a new Herndon Capital Management position in Q2 2017.
Eagle Pharmaceuticals, Inc. made up ﹤0.01% of Herndon Capital Management's portfolio in Q2 2017, its #191 holding.
175 funds tracked by Wall St. Rank held Eagle Pharmaceuticals, Inc. as of Q2 2017.

Based on Herndon Capital Management's 13F filing for Q2 2017, filed 4 Aug 2017.